AstraZeneca, a global pharmaceutical leader, has embarked on a transformative journey in clinical trials by integrating digital health solutions. This innovative approach not only improves the patient experience but also accelerates trial timelines and reduces costs.
In the paper titled “Implementation of digital health technology in Clinical Trials: the 6R framework ”, the authors emphasized that traditional clinical trials have typically relied on in-person patient visits for various stages, including recruitment, interventions, assessments, and follow-ups. While in-person contact is valuable, it can pose significant challenges for patients in terms of time, logistics, and costs.
To uncover the benefits and results, AstraZeneca conducted qualitative research involving 322 patients, caregivers, and trial investigators from 9 countries (the USA, the UK, Germany, Sweden, Russia, China, South Korea, Japan, and Poland) to gain insights into their experiences of participating in clinical trials.
We are proud to announce that our cloud-based AI solution, ArtiQ.QC has contributed to this research. ArtiQ.QC was used to perform real-time quality control of the spirometry to ensure high-quality data collection during clinical trials.
According to this study, using AI for real-time quality control in spirometry can reduce missing data due to errors by about 5%, compared to collecting data at the clinic.
We are honored to be a part of this journey toward integrating digital solutions into everyday clinical trial practices, which aligns perfectly with our mission. We are looking forward to contributing to future milestones and continuing to push the boundaries of clinical trials.
.
Read the full paper here: https://www.nature.com/articles/s41591-023-02489-z